CN111602821A - 一种含有唾液酸和dha的微胶囊及其制备方法 - Google Patents
一种含有唾液酸和dha的微胶囊及其制备方法 Download PDFInfo
- Publication number
- CN111602821A CN111602821A CN202010457670.1A CN202010457670A CN111602821A CN 111602821 A CN111602821 A CN 111602821A CN 202010457670 A CN202010457670 A CN 202010457670A CN 111602821 A CN111602821 A CN 111602821A
- Authority
- CN
- China
- Prior art keywords
- dha
- sialic acid
- containing sialic
- microcapsule containing
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 81
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims abstract description 81
- 239000003094 microcapsule Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 172
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 86
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 86
- 239000000463 material Substances 0.000 claims abstract description 32
- 239000002131 composite material Substances 0.000 claims abstract description 30
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 29
- 239000000341 volatile oil Substances 0.000 claims abstract description 20
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 19
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 19
- 239000001527 calcium lactate Substances 0.000 claims abstract description 19
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims description 29
- 238000003756 stirring Methods 0.000 claims description 20
- 239000000839 emulsion Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229920002494 Zein Polymers 0.000 claims description 12
- 239000005019 zein Substances 0.000 claims description 12
- 229940093612 zein Drugs 0.000 claims description 12
- 241000147041 Guaiacum officinale Species 0.000 claims description 11
- 229940091561 guaiac Drugs 0.000 claims description 11
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 11
- 229950004354 phosphorylcholine Drugs 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 4
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 6
- 230000000638 stimulation Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 5
- 238000012545 processing Methods 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 19
- 241000779819 Syncarpia glomulifera Species 0.000 description 8
- 239000001739 pinus spp. Substances 0.000 description 8
- 229940036248 turpentine Drugs 0.000 description 8
- 241000119909 Elsholtzia bodinieri Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明属于食品加工技术领域,具体涉及一种含有唾液酸和DHA的微胶囊及其制备方法。本发明提供的含有唾液酸和DHA的微胶囊包含如下组分及其重量百分数:唾液酸15~25%,DHA 15~25%,芬多精精油0.3~0.5%,乳酸钙0.5~0.8%,乳化剂1~2%,复合壁材46.7~68.2%。本发明提供的含有唾液酸和DHA的微胶囊,采用的均为天然化合物,对人体刺激作用小,可以快速被吸收,且无残留,还具有一定的杀菌功效。
Description
技术领域
本发明属于食品加工技术领域,具体涉及一种含有唾液酸和DHA的微胶囊及其制备方法
背景技术
唾液酸(Sialic acid):唾液酸是9-碳单糖的衍生物。名字来自于希腊文σιαλοσ(sialos)'saliva'.这是一种能使唾液产生光滑感觉的负电荷离子。它不仅据有"诱导"入侵病菌的作用,目前认知是神经节苷脂的传递递质,并且是大脑的组成部分。唾液酸可以阻止病菌入侵。唾液酸同时也是流感病毒的受体,是流感病毒结合在黏液细胞中的结合位点。
DHA(docosahexaenoic acid,DHA),二十二碳六烯酸,俗称脑黄金,是一种对人体非常重要的不饱和脂肪酸,DHA是神经系统细胞生长及维持的一种主要成分,是大脑和视网膜的重要构成成分,在人体大脑皮层中含量高达20%,在眼睛视网膜中所占比例约50%,对胎婴儿智力发育至关重要。作为一种必需脂肪酸,其增强记忆与思维能力、提高智力等作用更为显著。人群流行病学研究发现,体内DHA含量高的人的心理承受力较强、智力发育指数也高。
DHA不仅对胎儿大脑发育有重要影响,而且对视网膜光感细胞的成熟有重要作用。孕妇在孕期可通过摄入富含α-亚麻酸的食物来提高α-亚麻酸的含量,利用母血中的α-亚麻酸合成DHA,然后输送到胎儿大脑和视网膜,使那里的神经细胞成熟度提高。
有研究显示,唾液酸的含量与DHA的含量有着明显的相关性,这表明两者都与脑结构和脑功能发育相关,有利于婴儿脑的早期发育。婴儿体内唾液酸和DHA含量状态依赖于外源食物中唾液酸和DHA的含量。因此孕妇应注意在孕期和妊娠期多摄入唾液酸和DHA,以促进胎儿大脑发育。
然而,唾液酸的稳定性极易受其他物质的影响,DHA由于含有活泼的亚基,极易极易发生氧化,对人体健康造成影响,这些问题不解决,我们难以获得可以同时补充唾液酸和DHA的产品。
基于此,中国专利CN104041827B公开了一种含有唾液酸和DHA的微胶囊及其制备方法,该微胶囊包含唾液酸10%~30%;DHA10%~30%;碳水化合物50%~80%;乳化剂0.5%~3%;具有稳定性强的优点,然而,这种微胶囊容易因吸收不干净,在体内残留,对人体产生刺激作用,且其成本高,仅适用于食品领域。
综上可知,现有技术中普遍存在成本高,适用范围广,容易对人体造成刺激作用,稳定性差等缺点。
发明内容
本申请的目的是针对现有技术中普遍存在的缺点,提供一种有唾液酸和DHA的微胶囊及其制备方法。本发明提供的含有唾液酸和DHA的微胶囊,制备过程简单,成本低,且可以被人体全部吸收,无残留,不会对人体产生刺激作用。
为了达到上述目的,本发明采用的技术方案为:
一种含有唾液酸和DHA的微胶囊,包括如下组分及其重量百分数:唾液酸15~25%,DHA 15~25%,芬多精精油0.3~0.5%,乳酸钙0.5~0.8%,乳化剂1~2%,复合壁材46.7~68.2%。
优选地,所述含有唾液酸和DHA的微胶囊,由如下组分及其重量百分数组成:唾液酸20%,DHA 20%,芬多精精油0.4%,乳酸钙0.7%,乳化剂1.5%,复合壁材52.4%。
优选地,所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比7~9:3~5:6~8组成。
优选地,所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比8:4:7组成。
优选地,所述复合壁材由玉米朊及松脂按重量比8~10:1~3组成。
优选地,所述复合壁材由玉米朊及松脂按重量比9:2组成。
本发明还提供了所述含有唾液酸和DHA的微胶囊的制备方法,包含如下步骤:
S1、将唾液酸,乳酸钙加入到水中,升温至35~45℃,搅拌溶解,得混合物I;
S2、向步骤S1所得混合物I中加入复合壁材及芬多精精油,升温至45~50℃,搅拌均匀,得混合物II;
S3、向步骤S2所得混合物II中加入乳化剂及DHA,降温至25~30℃,磁力搅拌乳化均匀,然后置于30~40MPa的压强下,二次均质20~30min,得混合均匀的乳化物;
S4、将步骤S3所得混合均匀的乳化物进行喷雾干燥,即得。
优选地,步骤S1中搅拌溶解的条件为于300~500rpm的速度下,搅拌40~50min。
优选地,步骤S2中搅拌均匀的条件为600~800rpm的速度下,搅拌30~40min。
优选地,步骤S4中喷雾干燥的具体操作为:将乳化物置于干燥室中雾化25~30min,使水分迅速汽化,即可。
本发明中,将唾液酸与DHA按一定比例同时加入,有助于提高人体内唾液酸及DHA的含量,促进人智力发育指数的提高及视网膜光感细胞的成熟,孕妇服用,还有助于促进胎儿的生长发育。
同时,本申请中添加了按一定比例混合的玉米朊及松脂组成复合壁材,为微胶囊提供一种膜结构,该膜结构无毒,降低了微胶囊对皮肤的刺激反应,且具有极强的稳定性,可以提高微胶囊的稳定性。而且,申请人意外的发现,将芬多精精油与乳酸钙加入到微胶囊中,可以促进微胶囊的消化吸收,避免其残留对人体产生刺激反应,还可以为人体补充钙元素,提高人体的免疫力。
与现有技术相比,本发明提供的含有唾液酸和DHA的微胶囊具有如下优点:
(1)本发明提供的含有唾液酸和DHA的微胶囊,添加了一种混合壁材,形成了一种无毒的膜结构,降低了微胶囊对皮肤的刺激反应,同时提高了微胶囊的稳定性;
(2)本发明提供的含有唾液酸和DHA的微胶囊,将芬多精精油与乳酸钙混合使用,可以为人体提供钙元素,显著提高了人体对微胶囊的消化吸收能力,避免因残留对人体产生刺激反应;
(3)本发明提供的含有唾液酸和DHA的微胶囊,制备过程简单,成本低,可以适用于制备药物、食品等,提高了微胶囊的使用范围。
具体实施方式
下面结合具体实施例对本发明作进一步解释,但是应当注意的是,以下实施例仅用以解释本发明,而不能用来限制本发明,所有与本发明相同或相近的技术方案均在本发明的保护范围之内。若未特别指明,实施例中所用的技术手段为本领域技术人员所熟知的常规手段,所用原料为市售商品。
其中,本发明所用试剂均为常用试剂,均可在常规试剂生产销售公司购买。
实施例1一种含有唾液酸和DHA的微胶囊
所述含有唾液酸和DHA的微胶囊,由如下组分及其重量百分数组成:唾液酸15%,DHA 15%,芬多精精油0.3%,乳酸钙0.5%,乳化剂1%,复合壁材68.2%;所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比7:3:6组成;所述复合壁材由玉米朊及松脂按重量比8:1组成。
所述含有唾液酸和DHA的微胶囊的制备方法为:
S1、将唾液酸,乳酸钙加入到水中,升温至35℃,于300rpm的转速下搅拌溶解40min,至完全溶解,得混合物I;
S2、向步骤S1所得混合物I中加入复合壁材及芬多精精油,升温至45℃,于600rpm的速度下搅拌30min,至搅拌均匀,得混合物II;
S3、向步骤S2所得混合物II中加入乳化剂及DHA,降温至25℃,磁力搅拌乳化均匀,然后置于30MPa的压强下,二次均质20min,得混合均匀的乳化物;
S4、将步骤S3所得混合均匀的乳化物置于干燥室中雾化25min,使水分迅速汽化,即得。
实施例2一种含有唾液酸和DHA的微胶囊
所述含有唾液酸和DHA的微胶囊,由如下组分及其重量百分数组成:唾液酸25%,DHA 25%,芬多精精油0.5%,乳酸钙0.8%,乳化剂2%,复合壁材46.7%;所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比9:5:8组成;所述复合壁材由玉米朊及松脂按重量比10:3组成。
所述含有唾液酸和DHA的微胶囊的制备方法为:
S1、将唾液酸,乳酸钙加入到水中,升温至45℃,于500rpm的转速下搅拌溶解50min,至完全溶解,得混合物I;
S2、向步骤S1所得混合物I中加入复合壁材及芬多精精油,升温至50℃,于800rpm的速度下搅拌40min,至搅拌均匀,得混合物II;
S3、向步骤S2所得混合物II中加入乳化剂及DHA,降温至30℃,磁力搅拌乳化均匀,然后置于40MPa的压强下,二次均质30min,得混合均匀的乳化物;
S4、将步骤S3所得混合均匀的乳化物置于干燥室中雾化30min,使水分迅速汽化,即得。
实施例3一种含有唾液酸和DHA的微胶囊
所述含有唾液酸和DHA的微胶囊,由如下组分及其重量百分数组成:唾液酸20%,DHA 20%,芬多精精油0.4%,乳酸钙0.7%,乳化剂1.5%,复合壁材52.4%;所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比8:4:7组成;所述复合壁材由玉米朊及松脂按重量比9:2组成。
所述含有唾液酸和DHA的微胶囊的制备方法为:
S1、将唾液酸,乳酸钙加入到水中,升温至40℃,于400rpm的转速下搅拌溶解45min,至完全溶解,得混合物I;
S2、向步骤S1所得混合物I中加入复合壁材及芬多精精油,升温至47℃,于700rpm的速度下搅拌35min,至搅拌均匀,得混合物II;
S3、向步骤S2所得混合物II中加入乳化剂及DHA,降温至27℃,磁力搅拌乳化均匀,然后置于35MPa的压强下,二次均质25min,得混合均匀的乳化物;
S4、将步骤S3所得混合均匀的乳化物置于干燥室中雾化27min,使水分迅速汽化,即得。
对比例1一种含有唾液酸和DHA的微胶囊
所述含有唾液酸和DHA的微胶囊,由如下组分及其重量百分数组成:唾液酸20%,DHA 20%,乳酸钙0.7%,乳化剂1.5%,复合壁材52.8%;所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比8:4:7组成;所述复合壁材由玉米朊及松脂按重量比9:2组成。
所述含有唾液酸和DHA的微胶囊的制备方法与实施例3类似;
与实施例3的区别在于,对比例1中不包含芬多精精油。
对比例2一种含有唾液酸和DHA的微胶囊
所述含有唾液酸和DHA的微胶囊,由如下组分及其重量百分数组成:唾液酸20%,DHA 20%,芬多精精油0.4%,乳酸钙0.7%,乳化剂1.5%,复合壁材52.4%;所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比1:1:1组成;所述复合壁材由玉米朊及松脂按重量比9:2组成。
所述含有唾液酸和DHA的微胶囊的制备方法与实施例3类似;
与实施例3的区别在于,对比例2中的乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比1:1:1组成。
对比例3一种含有唾液酸和DHA的微胶囊
所述含有唾液酸和DHA的微胶囊,由如下组分及其重量百分数组成:唾液酸20%,DHA 20%,芬多精精油0.4%,乳酸钙0.7%,乳化剂1.5%,复合壁材52.4%;所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比8:4:7组成;所述复合壁材由玉米朊及松脂按重量比1:1组成。
所述含有唾液酸和DHA的微胶囊的制备方法与实施例3类似;
与实施例3的区别在于,对比例3中的复合壁材由玉米朊及松脂按重量比1:1组成。
试验例1刺激性试验
1.试验样品:实施例1-3及对比例3制得的含有唾液酸和DHA的微胶囊
2.试验动物:体重为180±30g,清洁级为3级的白豚鼠60只,随机分成5组,每组12只,试验期间每只动物单独饲养,且所有动物无明显皮肤损伤。
3.试验方法:试验前24h,取所有试验动物,用理发推子和刀片在其背部两侧各作约20cm2的去毛处理,形成试验对比。
然后,将上述试验样品加水稀释成15mg/mL的溶液,用生理盐水作为空白对照,用药组在左侧去毛区用皮肤斑贴含1mL试验溶液的湿巾,对照组贴生理盐水湿巾,然后用不透气胶布包扎,保证药液留置于去毛区皮肤6h以上,用药24h后用无刺激性的生理盐水洗去残留药液,然后于洗除残药后1、24、72h观察受药部位皮肤有无红斑,水肿等情况,进行皮肤刺激反应评分。评分标准按GB/T16886.10-2005进行。
评价结果:极轻微:0.0~0.4分;轻度0.5~1.9分;中度2.0~4.9分;重度5.0~8.0分。
4.试验结果:具体试验结果见表1。
表1不同试验样品的刺激反应评分结果
由表1可知,本发明实施例1-3制得的含有唾液酸和DHA的微胶囊对人体的刺激性极小,评分均在0.4以下,属于极轻微刺激,尤其是实施例3组的评分仅为0.1左右,可以认为对人体无刺激作用,故实施例3为本发明的最佳实施例。而对比例3中,改变了复合壁材的组分,破坏了膜的完整性,导致对人体的刺激性大大增加。
试验例2稳定性试验
1.试验样品:实施例1-3及对比例2-3制得的含有唾液酸和DHA的微胶囊。
2.试验方法:光照试验:取上述样品各5g,分成10份,置于4000LX灯箱中,分别于24点,3天,5天,10天取样测定吸光度值,计算保存率,取10个样品的平均值作为最终的保存率。
高温试验:取上述样品各5g,分成10份,置于70℃恒温培养箱中,分别于24点,3天,5天,10天取样测定吸光度值,计算保存率,取10个样品的平均值作为最终的保存率。
保存率=(测定吸光度/初始吸光度)×100%
3.试验结果:具体试验结果见表2。
表2温度及光照对不同试验样品稳定性的影响
由表2可知,本发明实施例1-3制得的含有唾液酸和DHA的微胶囊,在强光、高温等条件下可以保持较好的稳定性,尤其是实施例3中,在强光或高温的条件下,10天后,保存率还可以达到74%以上,稳定性极强,故实施例3为本发明的最佳实施例。而对比例2改变了乳化剂各组分的含量,对比例3改变了复合壁材的各组分的含量,导致稳定性均下降,尤其是对比例3中的壁材形成的膜改变后,导致稳定性大大降低。
试验例3消化吸收功能试验
1.试验样品:实施例1-3及对比例1-3制得的含有唾液酸和DHA的微胶囊。
2.试验对象:取清洁级昆明小鼠70只,随机分成7组,每组10只。受试者要求:皮肤健康,无皮肤病史,且皮肤色差不明显。
3.试验方法:试验分为实验组及空白对照组,试验组饲喂本发明试验样品,空白对照组饲喂生理盐水。
各组小鼠皮下注射盐酸吗啡2.5mg/(kg·日),共5天,并于第1天以75%酒精棉球擦拭小鼠尾部使血管扩张充血,剪去鼠尾尖端0.3cm,然后将鼠尾伤口浸入37℃左右温水中,直至小鼠失去血液约0.5ml,制成血虚型便秘模型。
造模同时,空白对照组小鼠灌胃生理盐水,6个试验组小鼠分别灌胃给予实施例1-3和对比例1-3制备的含有唾液酸和DHA的微胶囊3g/kg体重。各组每天给药1次,连续5天。末次给药时,蒸馏水及药液中加入2%印度墨汁指示剂。
末次给药后,各组小鼠分别置于铺有滤纸的烧杯内进行观察,记录排出第1粒黑色粪便的平均时间,同时记录末次给药4小时内平均排便的总粒数和平均粪便重量。
4.试验结果:具体试验结果见表3。
表3不同试验样品对小鼠肠运动的影响
试验样品 | 平均排便时间(min) | 平均排便粒数(粒) | 平均粪便重量(mg) |
空白对照组 | 97.5 | 15.8 | 231.4 |
实施例1 | 108.3 | 20.1 | 243.7 |
实施例2 | 109.4 | 19.7 | 239.9 |
实施例3 | 106.2 | 21.4 | 247.6 |
对比例1 | 176.5 | 15.4 | 157.8 |
对比例2 | 159.3 | 16.1 | 171.6 |
对比例3 | 153.8 | 16.7 | 182.5 |
由表3可知,本发明实施例1-3组制得的含有唾液酸和DHA的微胶囊,可以显著提高消化吸收功能,尤其是实施例3组的平均排便时间仅为106min,只比生理盐水多了9min左右,可以尽快被人体消化吸收,故实施例3为本发明的最佳实施例,而对比例1中,去掉了芬多精精油,导致消化吸收能力显著降低,对比例2-3由于改变了某些组分的比例,也对微胶囊的消化吸收能力造成了影响。
最后应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明做了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (10)
1.一种含有唾液酸和DHA的微胶囊,其特征在于,包括如下组分及其重量百分数:唾液酸15~25%,DHA 15~25%,芬多精精油0.3~0.5%,乳酸钙0.5~0.8%,乳化剂1~2%,复合壁材46.7~68.2%。
2.如权利要求1所述的含有唾液酸和DHA的微胶囊,其特征在于,由如下组分及其重量百分数组成:唾液酸20%,DHA 20%,芬多精精油0.4%,乳酸钙0.7%,乳化剂1.5%,复合壁材52.4%。
3.如权利要求1或2所述的含有唾液酸和DHA的微胶囊,其特征在于,所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比7~9:3~5:6~8组成。
4.如权利要求3所述的含有唾液酸和DHA的微胶囊,其特征在于,所述乳化剂由爱生兰,愈创木胶及磷酸胆碱按重量比8:4:7组成。
5.如权利要求1或2所述含有唾液酸和DHA的微胶囊,其特征在于,所述复合壁材由玉米朊及松脂按重量比8~10:1~3组成。
6.如权利要求5所述含有唾液酸和DHA的微胶囊,其特征在于,所述复合壁材由玉米朊及松脂按重量比9:2组成。
7.一种如权利要求1-6任一项所述含有唾液酸和DHA的微胶囊的制备方法,其特征在于,包含如下步骤:
S1、将唾液酸,乳酸钙加入到水中,升温至35~45℃,搅拌溶解,得混合物I;
S2、向步骤S1所得混合物I中加入复合壁材及芬多精精油,升温至45~50℃,搅拌均匀,得混合物II;
S3、向步骤S2所得混合物II中加入乳化剂及DHA,降温至25~30℃,磁力搅拌乳化均匀,然后置于30~40MPa的压强下,二次均质20~30min,得混合均匀的乳化物;
S4、将步骤S3所得混合均匀的乳化物进行喷雾干燥,即得。
8.如权利要求7所述含有唾液酸和DHA的微胶囊的制备方法,其特征在于,步骤S1中搅拌溶解的条件为于300~500rpm的速度下,搅拌40~50min。
9.如权利要求7所述含有唾液酸和DHA的微胶囊的制备方法,其特征在于,步骤S2中搅拌均匀的条件为600~800rpm的速度下,搅拌30~40min。
10.如权利要求7所述含有唾液酸和DHA的微胶囊的制备方法,其特征在于,步骤S4中喷雾干燥的具体操作为:将乳化物置于干燥室中雾化25~30min,使水分迅速汽化,即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010457670.1A CN111602821A (zh) | 2020-05-26 | 2020-05-26 | 一种含有唾液酸和dha的微胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010457670.1A CN111602821A (zh) | 2020-05-26 | 2020-05-26 | 一种含有唾液酸和dha的微胶囊及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111602821A true CN111602821A (zh) | 2020-09-01 |
Family
ID=72194867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010457670.1A Pending CN111602821A (zh) | 2020-05-26 | 2020-05-26 | 一种含有唾液酸和dha的微胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111602821A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101485465A (zh) * | 2009-02-18 | 2009-07-22 | 湖南轻工研究院有限责任公司 | 食用微胶囊矿物质营养盐及其制备方法 |
CN102755328A (zh) * | 2011-04-29 | 2012-10-31 | 上海医药工业研究院 | 积雪草酸盐微乳软胶囊及其制备方法 |
CN104041827A (zh) * | 2014-06-30 | 2014-09-17 | 江苏布诺堂健康生物科技有限公司 | 一种含有唾液酸和dha的微胶囊及其制备方法 |
CN109463761A (zh) * | 2018-10-15 | 2019-03-15 | 嘉必优生物技术(武汉)股份有限公司 | 一种含有唾液酸的pufa油悬液及其制备方法 |
-
2020
- 2020-05-26 CN CN202010457670.1A patent/CN111602821A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101485465A (zh) * | 2009-02-18 | 2009-07-22 | 湖南轻工研究院有限责任公司 | 食用微胶囊矿物质营养盐及其制备方法 |
CN102755328A (zh) * | 2011-04-29 | 2012-10-31 | 上海医药工业研究院 | 积雪草酸盐微乳软胶囊及其制备方法 |
CN104041827A (zh) * | 2014-06-30 | 2014-09-17 | 江苏布诺堂健康生物科技有限公司 | 一种含有唾液酸和dha的微胶囊及其制备方法 |
CN109463761A (zh) * | 2018-10-15 | 2019-03-15 | 嘉必优生物技术(武汉)股份有限公司 | 一种含有唾液酸的pufa油悬液及其制备方法 |
Non-Patent Citations (2)
Title |
---|
孙兰萍等: "食品成分微胶囊制备技术及发展趋势展望", 《农产品加工(学刊)》 * |
林静等: "5 种康养植物芬多精成分及含量研究", 《四川林业科技》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khory et al. | Materica medica of India and their therapeutics | |
US2320479A (en) | Topical remedy | |
US2060336A (en) | Composition of matter containing vegetable mucinous extract from plants | |
CN104739921A (zh) | 一种用于缓解视疲劳的组方含片及其制备方法 | |
CN105816848A (zh) | 一种祛湿防护膏及其制备方法 | |
CN114796300A (zh) | 一种丝瓜全汁冻干粉的制备方法、丝瓜全汁冻干粉及其应用 | |
JP3720496B2 (ja) | 新規ペクチン及びそれを含有する乳化液 | |
AU2020102282A4 (en) | Immunity-boosting gel candy for children and the method of preparation | |
CN106590921B (zh) | 一种精制蛇油的生产加工工艺 | |
CN111602821A (zh) | 一种含有唾液酸和dha的微胶囊及其制备方法 | |
JP2004229534A (ja) | 加水分解卵殻膜含有飲料 | |
CN110898027A (zh) | 促进血钙入骨的维生素k2(mk-7)软胶囊及制备方法 | |
US2341986A (en) | Therapeutic confection | |
CN105534749A (zh) | 一种儿童益智牙膏 | |
CN1895275A (zh) | 一种小牛血去蛋白提取物凝胶剂 | |
CN112042798A (zh) | 一种增强儿童免疫力的凝胶糖果及其制备方法 | |
JP2015536976A (ja) | 浣腸剤 | |
CN106937731A (zh) | 蜂王幼虫粉提取物及其制备方法和应用 | |
RU2253328C2 (ru) | Биологически активная добавка к пище "маривит" и способ ее производства | |
DE60306877T2 (de) | Die Blut-Fluidität verbessernde Lebensmittel | |
Bastedo | Materia Medica: Pharmacology, Therapeutics and Prescription Writing for Students and Practitioners | |
CN111000974B (zh) | 一种兔奶活性小肽溶液及其提取方法和应用 | |
JPH09187248A (ja) | 抗アレルギー食品 | |
Jacobi | The Intestinal diseases of infancy and childhood v. 2 | |
CN105832773A (zh) | 一种用动物胆汁制备的多功能复合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221221 Address after: 475300 3rd floor, North Funuo health building, Yulu Avenue, Lankao County, Kaifeng City, Henan Province Applicant after: Funo health Co.,Ltd. Address before: 510700 Room 405, building 3, No. 257, Junye Road, Huangpu District, Guangzhou City, Guangdong Province Applicant before: GUANGZHOU FUNUO NUTRITION TECHNOLOGY Co.,Ltd. |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200901 |